For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Orexin A Induces GnRH Gene Expression and Secretion from GT1-7 Hypothalamic GnRH NeuronsSasson R. · Dearth R.K. · White R.S. · Chappell P.E. · Mellon P.L.
Departments of Reproductive Medicine and Neuroscience and the Center for Reproductive Science and Medicine, University of California at San Diego, La Jolla, Calif., USA Corresponding Author
Pamela L. Mellon
Department of Reproductive Medicine, University of California, San Diego
3A14 Leichtag Biomedical Research Building, 9500 Gilman Drive
La Jolla, CA 92093-0674 (USA)
Tel. +1 858 534 1312, Fax +1 858 534 1438, E-Mail email@example.com
Orexin A, a recently discovered hypothalamic peptide, has been shown to have a stimulatory effect on release of gonadotropin-releasing hormone (GnRH) from rat hypothalamic explants in vitro. However, it is presently unclear whether in vivo this effect is mediated directly at the level of the GnRH neuron, or via multiple afferent neuronal connections. Therefore, in the present study, we investigated the direct action of orexin A on GnRH neurons using the immortalized GnRH-secreting GT1-7 hypothalamic cells. Orexin-1 receptor (OX1R) expression was detected in GT1-7 cells by RT-PCR and Western blot. Results showed that 0.1–1 nM orexin A, when administered in culture media for 4 h, can significantly stimulate GnRH mRNA expression in GT1-7 cells (p < 0.05). Administration of 1 µM OX1R antagonist, SB-334867, completely blocked the observed orexin A responses in these cells, indicating that orexin A stimulation of GnRH neurons is specifically through OX1R. Moreover, 0.1 nM orexin A stimulated GnRH release after 30–45 min. To examine possible signal transduction pathways involved in mediating these effects, a MEK inhibitor (UO-126), PKC inhibitor (calphostin C), and PKA inhibitor (H-89), were used, with each blocking orexin A-induced GnRH transcription and release from immortalized cells. Collectively, our results show that orexin A is capable of directly stimulating GnRH transcription and neuropeptide release from these immortalized hypothalamic neurons, and that the effects of orexin A appear to be mediated via the OX1R, coupled with activation of the PKC-, MAPK- and PKA-signaling pathways. It is suggested that the stimulatory effect of orexin A on GnRH transcription and release may also occur directly at the level of GnRH neurons in vivo.
© 2006 S. Karger AG, Basel
The 33-amino-acid peptide orexin A, also known as hypocretin A, is a hypothalamic neuropeptide that has been shown to increase food intake and to be involved in the control of energy metabolism [reviewed in [1,2,3]]. A single precursor peptide undergoes proteolytic cleavage to produce both orexin A and orexin B, a 28-amino-acid neuropeptide . Previous studies have indicated that, due to structural differences, orexin A has greater resistance to degradation and appears to be more physiologically potent than orexin B [5, 6]. The actions of orexins are mediated via two G protein-coupled receptors, the orexin-1 receptor (OX1R) and orexin-2 receptor (OX2R) .
Orexin mRNA expression and immunoreactive orexins are mainly localized to the lateral hypothalamus, the posterior hypothalamus, and the perifornical nucleus . Intraventricular administration of orexin A mildly stimulates food intake and energy expenditure. The orexin/hypocretin system is best known for its role in the maintenance of arousal and waking [reviewed in  and ]. Specifically, orexins are strongly implicated in the pathogenesis of narcolepsy [8, 9], a chronic neurological disorder characterized by sudden, brief episodes of sleep that interrupt normal waking [reviewed in ].
Recent physiological and neuroanatomical studies suggest that orexin A may play a role in the homeostatic regulation of the hypothalamic-pituitary gonadal axis [5,11,12,13]. Changes in orexin A release occur concomitant with the estrous cycle in adult female rats, increasing in early proestrus and decreasing in late proestrus . Furthermore, an intracerebroventricular administration of orexin A has been shown to cause recovery of both luteinizing hormone (LH) and prolactin levels that were decreased subsequent to fasting  and prepro-orexin mRNA expression is decreased in both ob/ob and fa/fa obese mice . These results suggest that orexin A may communicate changes in metabolic state to the reproductive axis. However, whether orexin A plays a substantial role in dictating reproductive status is poorly understood.
The recent discovery of alterations in gonadotropin secretion by neuropeptides involved in food regulation has provided evidence linking metabolic homeostasis with reproduction. Gonadotropin-releasing hormone (GnRH) secretion is mandatory for reproductive function [17, 18] and alterations in GnRH neuronal secretion induced by metabolic neuropeptides result in precocious/delayed puberty [19, 20], athletic amenorrhea , disrupted menstrual/estrous cycles  and infertility . Studies have shown that GnRH cell bodies in the rat are co-localized with the orexin A ligand-specific OX1R , and orexin-immunoreactive terminals are found in close proximity with GnRH cells in the preoptic area of sheep . Orexin A dose-dependently inhibited GnRH-stimulated LH release in dispersed pituitaries from proestrous females only . Taken together, these studies suggest an association between orexin A and GnRH signaling; however, whether orexin A directly stimulates GnRH neurons to alter patterns of expression and/or secretion is not known. Notably, orexin A has been shown to induce GnRH release from hypothalamic explants from proestrus rats , and intracerebroventricular administration of orexin A antiserum inhibits the preovulatory LH surge in steroid-primed ovariectomized rats , implying that orexin A may have the ability to directly regulate GnRH secretion, subsequently modulating gonadotropin release. Thus, the present study was conducted to determine if orexin A can act directly on GnRH neurons to alter hormonal release and expression in vitro using immortalized GnRH-secreting GT1-7 hypothalamic cells. Because there are a limited number of GnRH neurosecretory cells that are dispersed throughout the preoptic area of the anterior hypothalamus , in vivo studies on the direct action of orexin A on GnRH transcription and secretion are difficult. A model of the GnRH neuron was developed through targeted tumorigenesis of the GnRH neuron by SV40 T antigen. Subsequently, a murine immortal cell line of GnRH-secreting hypothalamic neurons, the GT1-7 cells, was established . These cells have many hallmarks of the differentiated GnRH neuron [28,29,30] including pulsatile secretion of GnRH [31,32,33]. In this study, we determined that orexin A stimulates GnRH release and mRNA expression from GT1-7 cells. Furthermore, using inhibitors for mitogen-activated protein kinase kinase (MEK), protein kinase C (PKC), and protein kinase A (PKA), we showed that each resulted in blockade of GnRH gene expression and release in the presence of orexin A implicating all of these pathways in the regulatory cascade. Finally, we demonstrated that orexin A activates the MAPK pathway by increasing the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) proteins in GT1-7 cells.
Human orexin A was obtained from Phoenix Pharmaceuticals, Inc. (Belmont, Calif., USA). A selective OX1R antagonist SB-334867 was purchased from Tocris (Ellisville, Mo., USA). MEK inhibitor, UO-126, and the PKC inhibitor, calphostin C, were obtained from Calbiochem (San Diego, Calif., USA). PKA inhibitor, N-(2-[p-bromocinnamylamino]-ethyl)-5-isoquinolinesulfonamide (H-89), was obtained from Sigma Chemical Co. (St. Louis, Mo., USA).
Eight male C57 Black mice (6 weeks of age) were purchased from Harlan Sprague Dawley (Indianapolis, Ind., USA), and housed for 2 weeks in the UCSD animal facility under standard conditions. At 8 weeks of age, mice were sacrificed by decapitation and the hypothalami were collected. Experimental procedures were approved by the Animal Subjects Committee of the University of California, San Diego.
In experiments measuring GnRH mRNA expression, GT1-7 cells were plated at a density of 0.5 × 106 cells/2-cm2 well in DMEM supplemented with 10% fetal calf serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 4.5 mg/ml glucose. The medium was changed to serum-free DMEM 16 h before treatment. Cells were treated with either PBS and/or dimethyl sulfoxide (0.1% DMSO) as vehicle controls or orexin A (0.1, 1, or 10 nM diluted in PBS with 0.1% BSA) for 4 h, after which the cells were lysed to obtain total RNA. This time frame is based on a previous study showing that orexin A does not degrade within 2 h in culture . GT1-7 cells were pretreated for 30 min with SB-334867 , a selective OX1R antagonist, and co-treated during orexin A treatment, to test the specificity of the changes in GnRH secretion induced by orexin (1 µM of SB-334867 diluted in DMSO vehicle). For signaling experiments, GT1-7 cells were pretreated for 30 min with the inhibitors to MEK (100 nM UO-126), PKA (10 µM H-89), or PKC (100 nM calphostin C), and co-treated during orexin A treatment (all inhibitors diluted in DMSO vehicle).
In experiments measuring GnRH release, GT1-7 cells were grown in a monolayer culture and maintained in 10-cm culture plates containing DMEM, supplemented with 10% fetal calf serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 4.5 mg/ml glucose. Cells were incubated under normal conditions (5% CO2/95% air atmosphere at 37°C) for 4 days following plating, or until plates were 80–90% confluent. Twenty-four hours prior to initial sampling, media was removed, plates were rinsed three times with serum-free media, and replaced with serum-free media. The next day, media was changed, again using serum-free media, then one basal sample (150 µl) was collected from every plate to use as baseline GnRH level at time zero. Then cells were challenged by PBS, DMSO (vehicle controls), inhibitors, and/or orexin A 0.1–1 nM, as noted in the figures. Media (150 µl) was collected at each time point to monitor changes in GnRH secretion over time or at 45 min for the dose response. At the end of the experiment, plates of GT1-7 cells were depolarized with 60 mM potassium chloride (KCl) to assess neuronal viability and general secretory function. Increases in secretion due to KCl were always at least four fold demonstrating viability and secretory function. Collected media samples were stored at –20°C until assayed by radioimmunoassay (RIA) for GnRH content. All inhibitors were used as noted above for mRNA studies.
Total RNA was isolated from confluent 10-cm plates of cells using Trizol (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer’s protocol. One microgram of total RNA isolated was reverse transcribed using SuperScript II enzyme (Invitrogen). Twenty microliters of the reverse transcriptase reactions were amplified using sequence-specific PCR primers for OX1R: forward 5′-GCTTTTTCATTGTCACCTACC-3′; reverse 5′-CAGATAACAGAGTGCAAAAACC-3′. Polymerase chain reaction conditions: 97°C for 3 min, then 94°C for 30 s, 56.5°C for 1 min, 72°C for 1 min for 35 cycles, then 72°C for 7 min. To check for possible artifacts generated by amplification of remnants of genomic DNA, control RT-PCR was performed and treated in an identical way but without reverse transcriptase enzyme in the first reaction mixture. Amplified fragments were resolved by 1% agarose gel electrophoresis and visualized by ethidium bromide staining.
RNA was obtained with Trizol reagent (Invitrogen) according to the manufacturer’s instructions. Contaminating DNA was removed with DNA-free reagent (Ambion, Inc., Austin, Tex., USA) and 2 µg RNA was reverse transcribed using Superscript III First-strand Synthesis System (Invitrogen). Quantitative real-time PCR was performed in iCycler from Bio-Rad Laboratories, Inc. (Hercules, Calif., USA), using QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, Calif., USA) and the following primers:
GnRH forward: CTACTGCTGACTGTGTGTTTG
GnRH reverse: CATCTTCTTCTGCCTGGCTTC
GAPDH forward: TGCACCACCAACTGCTTAG
GAPDH reverse: GGATGCAGGGATGATGTTC
under the following conditions: 95°C for 15 min, followed by 40 cycles at 95°C for 15 s, 54°C for 30 s, and 72°C for 30 s. For GnRH and GAPDH measurements, the equivalent of 10 ng of starting RNA (as quantified before reverse transcription) was used in each reaction. Each sample was assayed in triplicate, and the experiment was repeated four times. A standard curve with dilutions of 1,000 pg/well, 100 pg/well, 10 pg/well, 1 pg/well, 100 fg/well, and 10 fg/well of a plasmid containing GnRH cDNA and GAPDH cDNA was generated in each experiment with the samples. In each experiment, the amount of GnRH was calculated by comparing threshold cycle obtained for each sample with the standard curve generated in parallel. After each experiment, a melting curve analysis was performed to confirm that a single amplicon was generated in each reaction.
Following overnight starvation and treatment with vehicle control or orexin A or SB-334867, GT1-7 cells were rinsed with PBS then lysed with lysis buffer containing 50 mM Hepes (pH 7.2), 150 mM NaCl, 1.5 mM MgCl2,1 mM EGTA, 1% Triton X-100, 10% glycerol, 30 mM NaF, 30 mM sodium pyrophosphate, 1 mM orthovanadate, and the protease inhibitors: aprotinin, pepstatin, leupeptin (10 µg/ml each), and 1 mM phenylmethylsulfonyl fluoride. Protein concentration was determined with Bradford reagent (Bio-Rad), then 30 µg protein per sample was loaded on a sodium dodecyl sulfate-polyacrylamide gel. After proteins had been resolved by electrophoresis and transferred to a polyvinylidene fluoride membrane, they were probed with specific antibodies for phosphorylated-ERK1/2, total-ERK1/2 (Upstate, Lake Placid, N.Y., USA), OX1R and actin (Santa Cruz Biotechnology, Santa Cruz, Calif., USA). The bands were detected with secondary antibodies linked to horseradish peroxidase and enhanced chemiluminescence reagent (Amersham Pharmacia, Piscataway, N.Y., USA) as described by the manufacturer.
GnRH primary antibody EL-14 was kindly provided by Martha Bosch, Oline Ronnekleiv, and Martin Kelly (University of Oregon Health Sciences Center, Portland, Oreg., USA). Briefly, 0.1 ml of each sample was incubated for 48 h with GnRH antibody at 4°C, after which time ∼10,000 cpm sample of radioiodinated GnRH (Amersham Pharmacia) was added. Forty-eight hours later, after ethanol precipitation of bound fractions, radioactivity was measured using a gamma counter (Micromedic, Huntsville, Ala., USA). Intra- and interassay variability was 5.3 and 6.4%, respectively.
Fold change in GnRH mRNA level for each treatment group was calculated by averaging replicates and by dividing them by the mean value of GAPDH in the same sample. GnRH mRNA is expressed as a ratio from control value for each treatment. GnRH release level for each treatment group was calculated by dividing the value of GnRH release of each treatment group by the level of GnRH present at time zero (basal level). All the experiments were repeated at least three times. Results represent the mean ± SEM of all samples analyzed. ‘#’ mark statistically significant differences in responses from the control cells determined by one-way ANOVA analysis followed by Turkey’s post-hoc multiple range test for individual comparison with p ≤ 0.05 or Student’s t test as indicated.
Using RT-PCR, we confirmed a previous report  showing that OX1R is expressed in GT1-7 cells (fig. 1a), when compared to positive hypothalamic tissue and negative controls (no RT), and not in fibroblast NIH3T3 cells. The mRNA expression level of OX1R was lower in LβT2 cells (immortalized pituitary gonadotropes) and was undetectable in GN11 (an immature GnRH neuronalcell line). In contrast, GT1-7 cells did not express the OX2R (data not shown). Western blot analysis validated our result detecting OX1R protein at approximately 51 kDa in GT1-7 cells as well as in gonadotrope cell lines, LβT2 and αT3-1 (fig. 1b). A relatively higher level of receptor protein was detected in GT1-7 cells compared to the RT-PCR analysis of its mRNA level, probably due to a higher stability or rate of translation of the protein in GT1-7 cells. Since orexin A selectively binds OX1R , these and other studies culminate to indicate that orexin A, but not orexin B, may play a larger role governing neuroendocrine functions and thus, orexin A is the peptide used in the following experiments.
GT1-7 cells were treated with increasing concentrations of orexin A (0.001–10 nM) for 4 h. We chose this time frame based on a previous study showing that orexin A does not degrade within 2 h in culture . Orexin A (0.1–1 nM) caused a significant increase in GnRH mRNA expression in GT1-7 cells after 4 h of treatment (fig. 2a). A time course showed that the maximal stimulation of gene expression was observed after 4 h of treatment with orexin A (fig. 2b). Consequently, all subsequent experiments were carried out at the concentration of 0.1 nM of orexin A for 4 h, which reflects the maximal stimulation.
To investigate whether OX1R mediates the stimulatory effect of orexin A on GnRH, we used the specific OX1R antagonist SB-334867 . GT1-7 cells were pretreated with 1 µM SB-334867 for 30 min before stimulation with 0.1 nM of orexin A for 4 h. The results show that the two-fold increase in GnRH mRNA expression by orexin A was abolished in the presence of SB-334867 (fig. 2c), indicating that orexin A alters GnRH mRNA expression via specific binding to the OX1R. Recent studies in Chinese hamster ovary cells have shown that OX1R couples to at least three different signaling pathways: (1) Gi/0 to inhibit cAMP generation; (2) Gs to stimulate cAMP generation, and (3) PKC (via PLC and Gq) to stimulate cAMP generation . To determine which signaling pathway(s) are utilized by orexin A to elicit increases in GnRH mRNA expression in GT1-7 cells, we administered a PKA inhibitor (H-89), a PKC inhibitor (calphostin C) or a MEK inhibitor (UO-126) to GT1-7 cells prior to and during orexin A stimulation (fig. 2c). Pretreatment with each of the inhibitors individually had no significant effect on basal GnRH mRNA expression in comparison to control cells. However, administration of each of the cell-signaling inhibitors resulted in a blockade of orexin A-induced GnRH mRNA expression (p < 0.05).
Orexin A (0.1 nM) significantly stimulated the release of GnRH from GT1-7 cells after 30 and 45 min (fig. 3). This rapid and transient action of orexin A on GT1-7 cells is consistent with that observed in a previous in vitro study using whole hypothalamicexplants . To investigate whether OX1R mediates the stimulatory effect of orexin A on GnRH secretion, we used the specific OX1R antagonist SB-334867 . GT1-7 cells were pretreated with 1 µM SB-334867 for 30 min before stimulation with 0.1 nM of orexin A for 45 min. Our results show that the four-fold increase in GnRH release by orexin A was abolished in the presence of SB-334867 (fig. 3c), indicating that orexin A alters GnRH secretion via specific binding to the OX1R.
We were also interested in investigating the signaling pathways involved in the orexin A-mediated stimulation of GnRH release in GT1-7 cells. To determine which signaling pathway(s) are involved in orexin A-mediated increases in GnRH secretion from GT1-7 cells, we administered a PKA inhibitor (H-89), a PKC inhibitor (calphostin C), or a MEK inhibitor (UO-126) to GT1-7 cells prior to and during orexin A stimulation (fig. 4a). Pretreatment with each of the inhibitors individually had no significant effect on GnRH release in comparison to control cells. However, administration of each of the cell-signaling inhibitors resulted in a blockade of orexin A-induced GnRH release (0.1 nM; p < 0.05), exhibiting secretory levels comparable to vehicle- and pre-treated controls. Supporting this, orexin A (0.1 nM) transiently increases ERK1/2 phosphorylation within 4 min in GT1-7 cells, as illustrated by the immunoblot in figure 4b. Moreover, in the presence of SB-334867, there was a visible reduction in ERK1/2 phosphorylation induced by treatment with orexin A for 8 min (fig. 4b).
The mammalian reproductive system is highly sensitive to changes in metabolic state, manifested by alterations in nutrient availability. Orexin A has been proposed to serve as a metabolic gate to the reproductive system to indicate that sufficient nutritional stores are available for reproduction. Orexin neurons exert at least part of this control through the facilitation of hypothalamic GnRH release, since it was shown that orexin A increased GnRH secretion from hypothalamic explants of intact males and femalesin vitro . Despite this finding, the mechanism of action of orexin A on GnRH neuronal function was unclear. In this study, we have confirmed that OX1R mRNA is expressed in GT1-7 cells, as was shown previously by Yang et al. . Moreover, we have shown the expression of OX1R at the protein level by Western blotting. In addition, OX1R expression was also detected at high level in the pituitary gonadotrope cell line, LβT2. This observation is consistent with studies in rats, human and sheep [39,40,41] supporting the potential role of orexin A in the regulation of reproductive neuroendocrine processes at the pituitary level. Furthermore, we demonstrated that orexin A likely stimulates GnRH mRNA expression and release in vivo by a direct action, using immortalized, GnRH-producing GT1-7 cells in vitro. This action appears to be primarily mediated by the OX1R subtype. No previous studies have been published on the responses of GnRH gene expression to orexin A in GT1-7 cells. In addition, orexin A increased GnRH mRNA expression. It is possible that orexin A affects gene transcription either directly and/or indirectly, and/or may have an effect on GnRH mRNA stability. Further studies are required to determine at what level orexin A acts to regulate GnRH mRNA levels. In a previous report, no effect of orexin A on GnRH release in GT1-7 cells was reported . However, in the current study, a lower concentration of orexin A was used (0.1 nM instead of 1 nM as the lowest dose), under different cell culture conditions. The most effective dose of orexin A that showed regulation of GnRH expression and release is 0.1 nM. The physiological concentration of orexin A in hypothalamic tissue has been shown to be dependent on the days of the estrous cycle in female rats . The hypothalamic orexin A concentration was 0.25 nM on the days of estrus and 0.7 nM on the days of proestrus . Therefore, the orexin A concentration used in our study is very close to the range of physiological concentrations of orexin A in the brain. This may explain the lack of response to orexin A in the Yang et al. [36 ]study, since they used a dose range of 1–500 nM. In addition, since orexin A is not only involved in signaling metabolic state, but also wakefulness and arousal [43, 44], a requirement for a low dose would prevent GnRH stimulation from occurring too indiscriminately. Another possible explanation for the lack of response to higher concentrations of orexin A is that OX1R may exist as a functional dimer in GT1-7 cells. It was demonstrated that OX1-R can heterodimerize with the cannabinoid CB1 receptor, which results in alterations of receptor localization and function . However, whether OX1Rs may exist and potentially function as homodimers remains to be examined. To our knowledge this is not the first demonstration of an atypical dose effect for a receptor. It is well described for both growth hormone and prolactin that activation of their receptors involves ligand-induced sequential receptor homodimerization. In an excess of ligand, they are unable to induce receptor dimerization due to the hormone’s ability to block the receptor in the inactive H1:R1 stoichiometry (one hormone, one receptor) [46, 47].
Corroborating our findings on GnRH stimulation in response to orexin A are numerous physiological and morphological studies supporting the concept of direct orexin A regulation of GnRH release in vivo. GnRH cell bodies in the rat are co-localized with the orexin A ligand-specific OX1R , and orexin-immunoreactive terminals are found in close proximity with GnRH cells in the preoptic area of sheep . Direct actions of orexin A on GnRH neurons are also suggested by the fact that orexin A can stimulate GnRH release from hypothalamic explants of intact males and femalesin vitro, also after 45 min , as we observed in our study. Moreover, intracerebroventricular administration of orexin A antiserum was shown to inhibit the preovulatory LH surge, implying that orexin A may have the ability to directly regulate GnRH secretion, thus modulating gonadotropin release . Additionally, it was shown very recently, by measuring the changes of the membrane potential of GnRH neurons, that orexin A, like NPY, had a direct effect on the GnRH neuron [M.S. Smith et al.: Abstract, Endocrine Society Annual Meeting, 2006]. Our findings of regulation of both GnRH mRNA expression and secretion by orexin A in GT1-7 cells support the hypothesis that the GnRH neurons of the hypothalamus are a direct target of orexin A.
PKA and PKC second messengers have been implicated in the regulation of GnRH gene expression in GT1-7 cells. Activation of PKA activity has been reported to have no effect  as well as inhibit  GnRH gene expression in GT1-7 cells. PKC signaling has been shown to downregulate GnRH gene expression [48, 50, 51]. In the present study, treatment with PKA or PKC inhibitors alone did not alter basal GnRH gene expression. These results support previous studies that showed that activation of adenylyl cyclase by forskolin, to raise cAMP levels, or treatment with the PKC inhibitor, bisindolylmaleimide, also had no effect on the steady-state level of GnRH mRNA levels over 48 and 24 h, respectively [48, 52]. In the presence of PKA or PKC inhibitors, there was a decrease in the orexin A-mediated increase of GnRH mRNA levels, suggesting that the PKA and PKC pathways may be involved in the orexin A-mediated induction of GnRH gene expression. OX1R has been shown to be able to activate Gi, Gs and Gq/11 proteins in Chinese hamster ovary cells . Since both Gi and Gq/11 proteins have been shown to activate the MAPK pathway [53,54,55], we decided to investigate the possible involvement of this signaling pathway in orexin A-mediated GnRH gene expression as well. Treatment with a MEK inhibitor did not alter basal GnRH mRNA expression, as has been shown in earlier study . In the presence of the MEK inhibitor, we showed that the response to orexin A is decreased, implying that the MAPK pathway is involved in orexin A-mediated increase in GnRH gene expression. Further studies will be aimed at identifying the downstream elements of these pathways involved in the induction of GnRH gene expression mediated by orexin A.
The signaling mechanisms involved in the regulation of GnRH secretion in GT1-7 cells are yet to be completely understood. Previous studies have shown the role of the PKA-signaling pathway in the stimulation of GnRH secretion, where dopamine and norepinephrine have been shown to increase intracellular cAMP levels and stimulate pulsatile GnRH secretion in GT1-7 cells . Stimulation of PKC activity has also been shown to enhance GnRH secretion from GT1-7 cells . Our results indicate that pharmacological inhibition of the PKA, PKC, or the ERK1/2 pathway resulted in inhibition of GnRH release induced by orexin A. These results suggest that all of these pathways are required for orexin A-mediated increase of GnRH secretion. These results support previous studies that showed that each of the PKA-, PKC- and MAPK-signaling pathways are involved in altering GnRH secretion . In particular, Roy and Belsham  have shown that all three of these pathways are necessary for melatonin-mediated suppression of GnRH secretion. A possible explanation for the observation of total blockade of the effects of orexin A by the inhibitors of the three signaling pathways is the evidence that the stimulatory effect of OX1R on adenylyl cyclase requires an interplay of PKC and Gs proteins in Chinese hamster ovary . In these cells, in the presence of Gs activity, the response of cAMP elevation by orexin A was fully dependent on PKCδ. Therefore, this could explain the cross-talk between the cellular signals that PKA and PKC triggers upon orexin receptor activation that are not fully independent signals. In our study on GnRH mRNAs using a pharmacological approach, we concluded that PKA, PKC and MAPK pathways are involved in the orexin A response, but since the orexin stimulation is modest in GT1-7 cells, it is difficult to judge the degree of the involvement of these pathways individually. It is of interest that each of these kinase inhibitors alone evoked a slight increase in GnRH secretion and expression that was not statistically significant, suggesting that, in the absence of a stimulatory factor such as orexin A, these signaling pathways are required for a basal repression of GnRH secretion. These results agree with another recent study that demonstrated that pharmacological inhibition of the PKA, PKC, or ERK1/2 pathways in GT1-7 neurons resulted in an increase in the basal secretion of GnRH .
We have also found that orexin A stimulation increases phosphorylation of ERK1/2, an action specifically mediated by OX1R. While little is currently understood about the mechanisms of regulation by the OX1R in GT1-7 cells, our results on phosphorylation of ERK1 and ERK2 are compatible with a recent study that demonstrated activation of ERK1/2 by orexin A in HEK-293T cells and in Chinese hamster ovary cells transfected with OX1R [59, 60].
In summary, these in vitro studies show that orexin A stimulates GnRH gene expression and release from GT1-7 cells, suggesting that this stimulatory effect of orexin A may also occur directly at the level of GnRH neurons in vivo. Future work will examine the effect of orexin A on GnRH neurons in situ to prove this hypothesis.
We thank Martha Bosch, Oline Ronnekleiv, and Martin Kelly for kindly providing the GnRH antibody. This work was supported by NIH/NIDDK R01 DK044838 to P.L.M. It was also supported by NIH/NICHD through a cooperative agreement (U54 HD012303) as part of the Specialized Cooperative Centers Program in Reproduction Research to P.L.M. R.K.D. and P.E.C. were supported in part by NIH T32 HD007203. P.E.C. was also supported by F32 DK10100 and K01 DK64919.
Pamela L. Mellon
Department of Reproductive Medicine, University of California, San Diego
3A14 Leichtag Biomedical Research Building, 9500 Gilman Drive
La Jolla, CA 92093-0674 (USA)
Tel. +1 858 534 1312, Fax +1 858 534 1438, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.